






FIG.1




















FIG.5

## Interleukine-2 receptor







FIG.6











FIG.8B










FIG.8C


•IL-4 ∘IL-4 IP130











Activity	+ + + +	DOCKE INV. Jac USSN 09 Reply to DATED	ET AL (703) 41 T # 201859US 0 ques THEZE ET 9/720,828 NOTICE REGA 06/28/2004 CEMENT DRAW	PCT AL. RDING DRAWIN	NGS (	QN	+	
Main molecular species	Telramer (4M-8M, Kd=30-100µM) /Octamer	Dimer (1M-2M, Kd=0,2pM) /Telramer (2M-4M, Kd=100pM)		Dimer (1M-2M, Kd=50µM) (2M-4M, Kd=1,4mM)	Dimer (1M-2m, Kd=113μM)	Monomer	Monomer	
% helix (Circular dichroism)	50% (150 λ 30μM) 35% (4μM)	22% (150 х 30µМ)	<2%	%0	% ()	%0	<5%	FIG. 10
1 10 20 30 APTTSSSTKKTQLQLEHLLLDLQMILNGINN	1 30	30	1 22	1 10	5 15	10 20	20 30	




FIG.11






FIG.11





NOITAJUMITS ON
(NIM 01) S-JI
(NIM 1) 0E19I
(NIM 2) 0E19I
(NIM 3) 0E19I
(NIM 3) 0E19I

FIG.12B





FIG.13



Model of transduction pathway induced by IP130 IL-2 receptor and its major signal transduction pathway

FIG. 14

NK cells (CD56 $^-$ ) entering in S+G2/M phases after IP130 stimulation (synergy with IL-2)

Treat	ment	J31	J32	J33	
IL-2 50 nM			14	12	14
	IP130	60µM	0	17	<u>≤</u> 5
	IP130	120µM	0	14	<5
IL-2 50 nM +	IP130	60µM	26	21	7
IL-2 50 nM +	IP130	120µM	28	28	28

FIG. 15

